斯金德林促进质瘤细胞的迁移和侵入,通过重塑actin细胞骨架
Xin Lin1, Zhao Zhao2, Shu-Peng Sun2
1Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin 300000, China. xnln69@aliyun.com.
World journal of clinical oncology
|January 31, 2024
概括
斯金德林 (SCIN) 通过激活RhoA/焦点粘附激酶 (FAK) 信号,促进质瘤细胞迁移和入侵,影响着actin细胞骨动力学. 这项研究强调了SCIN作为质瘤治疗的潜在治疗点.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 分子生物学分子生物学
背景情况:
- 质瘤是一种常见的内瘤,具有侵入性生长和不良预后.
- 动氨酸细胞骨重组对于瘤细胞迁移至关重要.
- 乙动态调节剂scinderin (SCIN) 参与癌细胞迁移和入侵.
研究的目的:
- 调查SCIN在质瘤中的作用和潜在机制.
- 确定SCIN表达在质瘤患者中的临床意义.
主要方法:
- 使用公共数据库分析SCIN表达和临床意义.
- 定量实时PCR和西部抹杀来评估SCIN表达.
- 通过短毛RNA (shRNA) 转染来抑制基因沉默.
- 细胞活力,迁移和入侵试验 (CCK-8,伤口愈合,Matrigel).
- 用F-actin染色来评估细胞骨组织.
主要成果:
- 在质瘤组织中,SCIN表达显著升高,与晚期瘤等级和野生型异酸盐脱酶相关.
- 在U87和U251质瘤细胞中,SCIN敲击降低了增殖,迁移和入侵.
- 抑制SCIN损害了RhoA/焦点粘附激酶 (FAK) 信号传递,导致F-actin脱聚合.
结论:
- 通过RhoA/FAK信号激活来调节actin细胞骨架,SCIN促进质瘤细胞的迁移和入侵.
- 在质瘤中,SCIN表现出促进癌症的作用.
- SCIN代表了质瘤治疗的潜在治疗点.
相关概念视频
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
Cytoskeletal Coordination in Cell Migration
4.8K
A migrating cell changes its shape during the cyclic events of attachment and detachment from the substratum and repositions the cell organelles correspondingly. These complex events are orchestrated by the dynamic cytoskeletal network comprising actin filaments, intermediate filaments, and microtubules. Cytoskeletal crosstalk — the direct and indirect communication between the different components — is crucial for this coordination. Direct communication involves various linker...
4.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


